Fabhalta 200 MG
Ended Awarded Last action
- Contract number
- 36C24526N0385
- Awardee
-
Novartis Pharmaceuticals Corporation UEI NG61ZA8TADW3
- Awarding agency
-
Veterans Integrated Service Network 5
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $34,874
Award facts
- Contract value 100% obligated
- $34,873.77 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Cary, NC 27513, USA
Award details come from SAM.gov/FPDS.
About this award
Novartis Pharmaceuticals Corporation received a delivery order valued at $34,873.77 for FABHALTA 200 mg from Veterans Integrated Service Network 5 (VISN 5), with performance in Cary, NC and completion targeted for March 13, 2026. This delivery order is issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) as a firm fixed-price contract with no small business set-aside designation. The award supports the Department of Veterans Affairs' pharmaceutical supply needs for specialized medical treatments and represents one of numerous delivery orders Novartis has received across multiple VISNs for cancer therapy and nuclear medicine products.
This delivery order falls under Novartis' broader federal contracting framework for pharmaceutical procurement. The company maintains multiple indefinite delivery vehicles with federal agencies, including a single-award Blanket Purchase Agreement with the National Acquisition Center valued at $61.1 million through October 2026 that authorizes FABHALTA procurement alongside other specialized oncology and nuclear medicine treatments. Novartis, a large foreign-owned pharmaceutical manufacturer headquartered in East Hanover, New Jersey, serves as a major federal supplier to the Veterans Health Administration and Defense Health Agency, with extensive experience delivering advanced cancer therapies and radiopharmaceutical products to support federal healthcare and veteran care missions.
Quick answers
Who was awarded contract 36C24526N0385?
36C24526N0385 was awarded to Novartis Pharmaceuticals Corporation by Veterans Integrated Service Network 5 (Veterans Health Administration) on March 6, 2026.
How much is contract 36C24526N0385 worth?
The government has obligated $34,874 on 36C24526N0385.
Is contract 36C24526N0385 an order under another contract?
Yes. 36C24526N0385 is a delivery order under 36F79720D0180, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24526N0385 competed?
The extent of competition for 36C24526N0385 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award